Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
bioAffinity Technologies develops noninvasive diagnostic tests for early lung cancer detection using flow cytometry and AI-driven analysis of sputum samples. Its flagship product, CyPath Lung, aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and support timely treatment. The company also explores therapeutic discoveries and operates a clinical laboratory, serving high-risk populations and healthcare providers worldwide in the growing cancer diagnostics market.
This description was generated via AI from an annual report. Updated about 1 year ago.